| Literature DB >> 35572407 |
Shruti Shandilya1, Sandeep Kumar2,3, Niraj Kumar Jha4, Kavindra Kumar Kesari1, Janne Ruokolainen1.
Abstract
Background: Recent research on the implications of gut microbiota on brain functions has helped to gather important information on the relationship between them. Pathogenesis of neurological disorders is found to be associated with dysregulation of gut-brain axis. Some gut bacteria metabolites are found to be directly associated with the increase in reactive oxygen species levels, one of the most important risk factors of neurodegeneration. Besides their morbid association, gut bacteria metabolites are also found to play a significant role in reducing the onset of these life-threatening brain disorders. Aim of Review: Studies done in the recent past raises two most important link between gut microbiota and the brain: "gut microbiota-oxidative stress-neurodegeneration" and gut microbiota-antioxidant-neuroprotection. This review aims to gives a deep insight to our readers, of the collective studies done, focusing on the gut microbiota mediated oxidative stress involved in neurodegeneration along with a focus on those studies showing the involvement of gut microbiota and their metabolites in neuroprotection. Key Scientific Concepts of Review: This review is focused on three main key concepts. Firstly, the mounting evidences from clinical and preclinical arenas shows the influence of gut microbiota mediated oxidative stress resulting in dysfunctional neurological processes. Therefore, we describe the potential role of gut microbiota influencing the vulnerability of brain to oxidative stress, and a budding causative in Alzheimer's and Parkinson's disease. Secondly, contributing roles of gut microbiota has been observed in attenuating oxidative stress and inflammation via its own metabolites or by producing secondary metabolites and, also modulation in gut microbiota population with antioxidative and anti-inflammatory probiotics have shown promising neuro resilience. Thirdly, high throughput in silico tools and databases also gives a correlation of gut microbiome, their metabolites and brain health, thus providing fascinating perspective and promising new avenues for therapeutic options.Entities:
Keywords: Alzheimer’s disease; Gut-microbiota; Neurodegeneration; Neurotherapeutics; Oxidative stress; Parkinson's disease
Mesh:
Substances:
Year: 2021 PMID: 35572407 PMCID: PMC9091761 DOI: 10.1016/j.jare.2021.09.005
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 12.822
Fig. 1Role of gut microbiota in neurodegeneration. (A) Communication between gut and the brain involves neural, metabolic, endocrine and immunological pathways. Gut microbial molecules like neurotransmitters, amino acids, short-chain fatty acids (SCFAs), amyloid, lipopolysaccharide (LPS) and microbe-associated molecular patterns (MAMPs) interacts with host immune system via circulation affecting metabolism and the nervous system of the host and, also it affects the brain by direct activation of the vagus nerve via enteric nervous system to the brain. Conditions like stress causes the hypothalamic neurons to secrete corticotrophic receptor harmone (CRH), triggering the release of adrenocorticotrophic releasing hormone (ACTH), subsequently activating the release of cortisol, which affects intestinal barrier integrity affecting gut health. (B) when, there occurs a condition of gut dysbiosis, there is a decrease of anti-inflammtory molecules (like SCFAs, H2) to that of pro-inflammatory molecules (LPS, amyloids) also with an alteration of beneficial bacteria to that of pathogenic in the gut. This results in increase of intestinal and blood brain barrier permeability, subsequently causing increase in peripheral immune responses, thus increasing oxidative stress in central nervous system (CNS). An increased production of reactive oxygen species (ROS) can be observed in cell organelles like mitochondria, endoplasmic reticulum (ER) and peroxisomes in neurons, along with neurotoxin aggregation, resulting in neurodegeneration.
Fig. 2Role of gut microbiota in neuroprotection. (A) Scheme of brain cell specific effects in response to beneficial metabolites released by gut microbiota in reducing inflammation and oxidative stress. (B) Fecal microbial transfer (FMT) which involves the transfer of fecal bacteria from healthy individual to one having pathological condition and was found to be an effective procedure in reducing the pathophysiology of neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and conditions like Multiple sclerosis (MS). (C) and (D) Antibiotic treatment and Probiotic treatment, respectively, which have shown the considerable effectiveness in decreasing the pathogenesis of neurodegenerative diseases. (E) The germ-free mice (mice free from gut microbiota), showed the decrease in neurodegenerative conditions and also used to study the effect of gut microbiota on brain physiology, thus showing the involvement of gut microbiota in neurodegeneration.
Summary of various reported studies on the role of gut microbiota in neuroprotection.
| Microbiota | Neurodegenerative disease | Model | Study outcome | Reference(s) |
|---|---|---|---|---|
| PD/AD | SH-SY5Y cells | Treatment with heat killed strain reduced Bax/Bcl-2 ratio and increased BDNF expression | ||
| AD | SH-SY5Y cells | Protected cells from Aβ-induced cytotoxicity | ||
| AD | 3xTg-AD mice | Diminished oxidative stress and inflammation, reduced levels of amyloid peptides and improved memory | ||
| ALS/HD | Restores lipid homeostasis and energy balance through mitochondrial β oxidation | |||
| AD | APP/PS1 mouse model of AD | Prevents Aβ deposition, microglia activation, production of TNF-α and IL-1β | ||
| AD | APPswe and | Ferulic acid produced by bacretia reduces oxidative stress, Aβ fibrillation and improves memory | ||
| AD/PD | NA | Proficient in producing butyrate, propionate and acetate | ||
| AD | D-galactose- induced AD mice model | ATPase enzyme levels and Na+ and K+ ATPase activity was restored required for potential neural activity | ||
| AD | 3xTg-AD mice | Inhibits Aβ deposition, decreased acylation of p53 protein along with increase in SIRT1 deacetylase activity and ADAM10-α secretase activity | ||
| NA | Oxidative stress induced Sprague Dawley rats and SH-SY5Y cells | Reduced ROS levels and increased SOD and GSH levels in oxidative stress condition | ||
| Lactobacillus acidophilus and | PD | Human PD patients | Reduced symptoms of abdominal pain and bloating | |
| PD | Human PD patients | Decreased movement disorder society-unified Parkinson’s disease rating scale scores | ||
| PD | Human PD patients | Improved abdominal symptoms | ||
| AD | Human AD patients | Decreased C- reactive protein (CRP) levels and insulin resistance and neuronal cell death | ||
| PD | 6-OHDA treated male Wister rats | Improved rotational behavior, cognitive function, lipid peroxidation, and neuronal damage | ||
| Lactobacillus acidophilus, Bifidobacterium bifidum and | AD | Animal model of AD | Improved cognitive performance and restored synaptic plasticity | |
| Age related neurodegeneration | C57BL/6 mice | Attenuated oxidative stress, improved gut barrier function and inhibited hepatic lipid accumulation | ||
| AD | Germ free mice | Decreased kynurenine and increased serotonin levels |
Overview of currently active databases related to neurological data.
| Database | Web address | Data type | Reference(s) |
|---|---|---|---|
| PDGene | Meta-analysis of genome-wide association studies (GWAS) | ||
| MDSGene | Genetic mutations, movement disorder genes related to PD | ||
| Alzforum | Repository of variants in genes linked to AD | ||
| AlzGene | Systematic meta-analyses of AD | ||
| Neuroinformatics Database (NiDB) | Imaging | ||
| Neuroscience Information Framework (NIF) | Metadata (imaging, genes, omics, function, grants, protocols etc.) | ||
| BrainMaps | Brain structure and function | ||
| Hippocampome Portal | Morphology, molecular marker, membrane biophysics and synaptic physiology | ||
| NeuroElectro | Electrophysiological properties | ||
| NeuroMorpho | Neuromorphology and metadata | ||
| NeuronDB | Voltage gated conductances, neurotransmitter receptors, and neurotransmitter substances | ||
| Collaborative Research in Computational | Electrophysiology and behavioral data | ||
| NeuroImaging Tools and Resources Collaboratory (NITRC) | Neuroimaging, imaging genomics software tools, data, and computational resources | ||
| BigBrain | Ultrahigh-Resolution 3D Human Brain Model | ||
| Brain Transcriptome database (BrainTx) | Gene expression | ||
| Marmoset Gene Atlas | Gene expression | ||
| Allen Brain Map | Metadata (gene expression, imaging | ||
| BrainCloud | Gene expression | ||
| M2IA | Microbiome and metabolome integrative analysis | ||
| Microbiota-Active Substance Interaction Database | Effect of bioactive compounds on microbiota and vice versa |